secwatch.observer — SEC 8-K summary
======================================

Issuer:     Processa Pharmaceuticals, Inc. (PCSA)
CIK:        0001533743
Form:       8-K
Filed at:   2026-04-30T23:59:59+00:00
Accession:  0001493152-26-020728
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Processa Pharmaceuticals transitions Chief Development Officer to part-time role effective May 1, 2026
--------------------------------------------------------------------------------

- Dr. Sian Bigora moves from full-time executive to part-time employee, retains Chief Development and Regulatory Officer title.
- She will no longer be an executive officer under Section 16 of the Exchange Act.
- Existing employment agreement terminated; replaced by new part-time arrangement effective May 1, 2026.
- Dr. Bigora retains all previously granted equity awards and remains eligible for prior bonus compensation.
- Transition is part of her planned path toward retirement, as stated by the company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533743/000149315226020728/0001493152-26-020728-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533743/000149315226020728/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-020728

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer